Breast cancer+2
Not recruitingStudy on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy
Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy
- Disease:Breast cancerHormone receptor positive breast cancer+1
- Substances:AbemaciclibFulvestrant+4
Poland- Participants:18–64 years · 65+ years
- Substances:Abemaciclib
- Sponsor:F. Hoffmann-La Roche AG












